Endpoints 100 survey 2025: Biotech CEOs are feeling more upbeatnews2025-12-11T12:00:03+00:00December 11th, 2025|Endpoints News|
Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firmnews2025-11-10T14:00:26+00:00November 10th, 2025|Endpoints News|
Special report 2025: Meet 20 women reshaping the future of biopharmanews2025-10-07T14:20:48+00:00October 7th, 2025|Endpoints News|
How past Endpoints 11 winners fared during 2025’s biotech downturnnews2025-09-03T11:00:44+00:00September 3rd, 2025|Endpoints News|
Who are the women reshaping biopharma R&D? Nominate them for Endpoints’ annual reportnews2025-06-09T11:00:36+00:00June 9th, 2025|Endpoints News|
Biopharma leaders carving a path for the industry’s LGBTQ+ communitynews2025-06-06T11:10:22+00:00June 6th, 2025|Endpoints News|
Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontentnews2025-05-20T11:00:54+00:00May 20th, 2025|Endpoints News|
Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15news2025-04-01T11:00:51+00:00April 1st, 2025|Endpoints News|
Endpoints’ LGBTQ+ list: Nominate for 2025news2025-02-25T13:00:31+00:00February 25th, 2025|Endpoints News|
Biotech is still trying to make CRISPR a successnews2025-02-19T15:00:35+00:00February 19th, 2025|Endpoints News|
